Citizens lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps an Outperform rating on the shares. Much of the pipeline opportunity is not valued at the moment and Crispr could initiate late-stage development in up to seven opportunities in 2027, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood Buys the Dip in Joby Aviation (JOBY), Sells Teradyne (TER) Near Highs
- Cathie Wood’s ARK Investment buys 127K shares of Crispr Therapeutics today
- Cathie Wood’s ARK Investment buys 120K shares of Crispr Therapeutics today
- Crispr Therapeutics price target lowered to $89 from $90 at BofA
- CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies